{
    "nctId": "NCT01880385",
    "briefTitle": "Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer",
    "officialTitle": "Efficacy & Safety of Bevacizumab as Neoadjuvant Treatment in Patients With Locally Advanced Inflammatory Breast Cancer, a Pilot Study.",
    "overallStatus": "UNKNOWN",
    "conditions": "Inflammatory Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "pathologic Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2022 Patients must have signed a written informed consent form prior to any study specific procedures,\n\n  * Women,\n  * 20 years or older,\n  * Performance status \\< 2 (ECOG),\n  * Histologically confirmed inflammatory breast cancer T4d any N,\n  * hormonal Status known,\n  * no metastases according to the last TNM classification,\n  * adequate hematologic function :\n\n    * absolute neutrophil count \u2265 1 500/mm3\n    * Platelets \u2265 100 000/mm3\n    * Hemoglobin \u2265 9 g/dL\n  * adequate liver function :\n\n    * ASAT and ALAT \\< \u00e0 3 ULN\n    * Alkaline Phosphatase \\< 5 ULN\n    * Total bilirubin \\< 1,5 ULN, o\n  * adequate kidney function :\n\n    * creatinine \\< 1,5 x normal or creatinine Clearance \u2265 50ml/min (according to the cockcroft and Gault formula)\n    * Urine Dipstick for proteinuria \\< 2+ patients who have proteinuria \u2265 2 + on dipstick urinalysis at baseline should undergo a 24 hours urine collection and must demonstrate \u2264 1 g of protein in 24 hours,\n  * adequate coagulation and cardiac function :\n\n    * Prothrombin ratio \u2265 70 % and,\n    * Prothrombin time \u2264 1,5 upper limit of normal (ULN) within 7 days prior to enrolment\n    * Left Ventricular ejection fraction (LVEF) \u2265 55 %\n\nExclusion Criteria:\n\n* Patients of childbearing potential with a positive pregnancy test (serum or urine) prior to enrollment\n* Patients who are either not post-menopausal, or surgically sterile, not using \"effective contraception\" (the definition of \"effective contraception\" will be based on the judgment of the investigator)\n* Patients who are pregnant or breastfeeding\n* Patient considered socially or psychological unable to comply with the treatment and the required medial follow-up,\n* Concurrent participation in another clinical trial or treatment with any other anticancer agent during the protocol specified period\n* Patients unwilling or unable to sign and date an Ethics Committee (EC)/ Institutional Review Board (IRB)-approved patient informed consent form\n* Patients unwilling or unable to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Non inflammatory breast cancer with lymphatic skin permeation, Metastases,\n* Bilateral breast cancer\n* Distant metastases (stage IV)\n* History of another cancer other than adequately treated carcinoma in situ of the cervix uteri, basal or squamous cell skin cancer\n* Prior anti tumor therapy (surgery, radiotherapy, chemotherapy, hormonal treatment and targeted therapy) except treatments given for carcinoma in situ of the cervix uteri, basal or squamous cell skin cancer\n* History or evidence of inherited bleeding diathesis or coagulopathy,\n* History of thrombotic disorders within the last 6 months prior to enrollment (i.e. cerebrovascular accident, transient ischemic attacks, subarachnoid hemorrhage),\n* Uncontrolled hypertension (systolic \\> 150 mmHg and/or diastolic \\> 100 mmHg)with or without any anti-hypertensive medication ; patients with high initial blood pressure are eligible if entry criteria are met after initiation or adjustment of anti-hypertensive medication,\n* Any of the following within 6 months prior to enrollment:\n\nmyocardial infarction, severe/unstable angina, or coronary/peripheral artery bypass graft surgery, clinically symptomatic and uncontrolled cardiovascular disease, or clinically significant cardiac arrhythmias (grade 3-4)\n\n* Severe resting dyspnea due to complications or oxygen dependency,\n* Diabetic patient treated with oral anti-diabetics or insulin with an underlying cardiopathy at ultrasound,\n* Any other severe acute illness such as active uncontrolled infections that would preclude the safe administration of study therapy at the time of the enrolment\n* Other severe underlying medical conditions, which could impair the ability to participate in the study\n* Major surgery, significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during study treatment,\n* Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion,\n* Non-healing wound, active peptic ulcer or bone fracture,\n* History of abdominal fistula, diagnosed with a trachea-oesophageal fistula or any grade 4 non gastro-intestinal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment,",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}